Sale Of Pfizer’s Established Products Not Off The Table, Exec Says
This article was originally published in The Pink Sheet Daily
Pfizer CFO Frank D’Amelio talks about the big pharma’s long-term vision and cost-reduction initiatives during the Morgan Stanley Healthcare conference. Management will continue reviewing the portfolio on an ongoing basis to see how best to maximize shareholder value, he said.
You may also be interested in...
In response to major market challenges, Big Pharmas have or are considering entering the small-molecule generics business. An IMS Consulting Group analysis of more than 4,500 generics launches between 2005 and 2010 tracks key attributes would-be branded company players need to know for success.
Pfizer is exercising its option to buy privately held NextWave Pharmaceuticals. The acquisition, which is expected to close in the fourth quarter, will give Pfizer the recently approved ADHD drug Quillivant XR.
Pfizer begins the process to split off its animal health business with an IPO in an effort to save on taxes and refrain from diluting the current shareholder base.